Study on different particle sizes of DOX-loaded mixed micelles for cancer therapy
Source abstract
Abstract
Nano-based drug delivery systems have been widely applied in cancer therapy, among that, particle sizes may affect the delivery efficiency of nanocarriers. The purpose of this study was to evaluate the potential impacts of particle size on tumor therapy, in consideration of this, lipid/glycocholic acid mixed micelles (LGs) were designed as the model nanocarriers. Doxorubicin (DOX) loaded LGs with two different particle sizes at around 10 nm and 100 nm, respectively, were successfully prepared by controlling the ratio of EPC to GAH. In vitro release study showed that the release behaviors of DOX in mixed micelles with two different particle sizes was basically consistent and showed sustained release. DOX-LGs at 10 nm exhibited higher cellular uptake capacity, compared with DOX-LGs at 100 nm. Besides, in vivo NIFR imaging also demonstrated that DOX-LGs at 10 nm had more accumulation in tumor site. Furthermore, DOX-LGs at 10 nm presented both higher in vitro cytotoxicity and superior in vivo antitumor activity than that of 100 nm. In vivo safety evaluations showed that the mixed micelles had lower toxicities than free DOX solution formulations. These results indicated that the nanoparticles with smaller particle size could improve the profiles in cellular uptake, tumor accumulation as well as anti-tumor efficacy, which would provide a theoretical principle for the design of nanoparticles.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Cancer statistics in China, 2015
2. Cancer statistics, 2020
3. Cancer chemoprevention is not a failure10.1093/carcin/bgu141 ↗
4. Tumour suppressor genes in chemotherapeutic drug response10.1042/BSR20110125 ↗
5. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration10.1021/nn504210g ↗
6. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo10.1016/j.jconrel.2013.10.020 ↗
7. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy10.1021/ja505212y ↗
8. A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy10.1016/j.jconrel.2016.03.037 ↗
9. Recent Advances of D-alpha-tocopherol Polyethylene Glycol 1000 Succinate Based Stimuli-responsive Nanomedicine for Cancer Treatment10.1007/s11596-020-2185-1 ↗
10. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma
11. Dual stimuli-guided lipid-based delivery system of cancer combination therapy10.1016/j.jconrel.2019.12.002 ↗
12. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
13. Nanotechnology in drug delivery and tissue engineering: from discovery to applications10.1021/nl102184c ↗
14. Transformable nanoparticles triggered by cancer-associated fibroblasts for improving drug permeability and efficacy in desmoplastic tumors10.1039/C9NR06438A ↗
15. Liver-Targeting and pH-Sensitive Sulfated Hyaluronic Acid Mixed Micelles for Hepatoma Therapy10.2147/IJN.S214528 ↗
16. Enhanced Primary Tumor Penetration Facilitates Nanoparticle Draining into Lymph Nodes after Systemic Injection for Tumor Metastasis Inhibition10.1021/acsnano.9b03472 ↗
17. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy10.1016/j.jconrel.2016.07.022 ↗
18. Strategies in the design of nanoparticles for therapeutic applications10.1038/nrd2591 ↗
19. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy10.1016/j.actbio.2018.07.014 ↗
20. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications10.1016/j.jconrel.2014.12.030 ↗
21. Liposome-based drug co-delivery systems in cancer cells10.1016/j.msec.2016.11.073 ↗
22. Carbon-Based Nanomaterials for Cancer Therapy via Targeting Tumor Microenvironment10.1002/adhm.201800525 ↗
23. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy
24. Progress in Nanomedicine: Approved and Investigational Nanodrugs
25. Nanomedicines: From Bench to Bedside and Beyond10.1208/s12248-016-9961-7 ↗
26. Size-Transformable Hyaluronan Stacked Self-Assembling Peptide Nanoparticles for Improved Transcellular Tumor Penetration and Photo-Chemo Combination Therapy10.1021/acsnano.9b08434 ↗
27. In vivo biodistribution of nanoparticles10.2217/nnm.11.79 ↗
28. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction10.2217/nnm.16.5 ↗
29. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters10.1016/j.ejpb.2007.08.001 ↗
30. Application of spray granulation for conversion of mixed phospholipid-bile salt micelles to dry powder form: influence of drug hydrophobicity on nanoparticle reagglomeration10.2147/IJN.S56215 ↗
31. Preparation and evaluation of self-assembly Soluplus((R))-sodium cholate-phospholipid ternary mixed micelles of docetaxel10.1080/03639045.2019.1660365 ↗
32. Investigation of solubilising effects of bile salts on an active pharmaceutical ingredient with unusual pH dependent solubility by NMR spectroscopy10.1016/j.ejpb.2015.02.016 ↗
33. Characterization of colloidal structures during intestinal lipolysis using small-angle neutron scattering10.1016/j.jcis.2017.03.109 ↗
34. The vesicle-to-micelle transformation of phospholipid-cholate mixed aggregates: a state of the art analysis including membrane curvature effects10.1016/j.bbamem.2010.09.002 ↗
35. A Mixed Micelle Formulation for Oral Delivery of Vitamin K10.1007/s11095-016-1954-9 ↗
36. A mixed micellar formulation suitable for the parenteral administration of taxol10.1023/A:1018943021705 ↗
37. pH-Responsive Hyaluronic Acid-Based Mixed Micelles for the Hepatoma-Targeting Delivery of Doxorubicin10.3390/ijms17040364 ↗
38. pH-Sensitive chitosan-tripolyphosphate nanoparticles increase doxorubicin-induced growth inhibition of cervical HeLa tumor cells by apoptosis and cell cycle modulation10.1016/j.colsurfb.2020.110897 ↗
39. Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer10.1016/j.actbio.2019.05.061 ↗
40. Inhibition of tumor-promoting stroma to enforce subsequently targeting AT1R on tumor cells by pathological inspired micelles10.1016/j.biomaterials.2018.01.023 ↗
41. Targeting self-assembly peptide for inhibiting breast tumor progression and metastasis10.1016/j.biomaterials.2020.120055 ↗
42. Preparation of polyethylene glycol-polyacrylic acid block copolymer micelles with pH/hypoxic dual-responsive for tumor chemoradiotherapy10.1016/j.colsurfb.2020.110943 ↗
43. Nanoparticle-mediated cellular response is size-dependent10.1038/nnano.2008.30 ↗
44. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size10.1038/nnano.2011.166 ↗
45. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy10.1021/acsami.6b09333 ↗